KCNH2

protein-coding gene in the species Homo sapiens

Uses your system voice; voice and rate in settings.

Q14865830Snapshot

≈ 3 min read

Names in other languages

  • العربيةقناة-HERG
  • DeutschKCNH2
  • EnglishKCNH2
  • FrançaisKCNH2
  • NederlandsKCNH2
  • srnKCNH2
  • 日本語HERG
  • 中文HERG

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Voltage-gated inwardly rectifying potassium channel KCNH2 also known as hERG (the human Ether-à-go-go-Related Gene) is a protein encoded by the gene KCNH2 K v 11.1, the α subunit of a potassium ion channel. This ion channel (sometimes simply denoted as 'hERG') is best known for its contribution to the electrical activity of the heart: the hERG channel mediates the repolarizing I Kr current in the cardiac action potential, which helps coordinate the heart's beating.

When this channel's ability to conduct electrical current across the cell membrane is inhibited or compromised, either by application of drugs or by rare mutations in some families, it can result in a potentially fatal disorder called long QT syndrome. Conversely, genetic mutations that increase the current through these channels can lead to the related inherited heart rhythm disorder short QT syndrome.

A number of clinically successful drugs in the market have had the tendency to inhibit hERG, lengthening the QT and potentially leading to a fatal irregularity of the heartbeat (a ventricular tachyarrhythmia called torsades de pointes). This has made hERG inhibition an important antitarget that must be avoided during drug development. hERG has also been associated with modulating the functions of some cells of the nervous system and with establishing and maintaining cancer-like features in leukemic cells.

Drug development considerations

Due to the documented potential of QT-interval-prolonging drugs, the United States Food and Drug Administration issued recommendations for the establishment of a cardiac safety profile during pre-clinical drug development: ICH S7B. The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals, issued as CHMP/ICH/423/02, adopted by CHMP in May 2005. Preclinical hERG studies should be accomplished in GLP environment.

Special K: Primate-specific Potassium Channel Variant Implicated in Schizophrenia - Schizophrenia Research Forum.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1378328115 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

3 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.